CellCarta is proud to have supported a number of studies that aim to advance the understanding and prognosis for various neurological disorders. Our neuroscience biomarker services are highlighted in several journals,including Science Translational Medicine.
","stat_1_value":"","stat_1_label":"","stat_2_value":"","stat_2_label":"","stat_3_value":"","stat_3_label":"","button_text":"Read More","button_url":"/publications/"},{"image_url":"https://cellcarta.com/wp-content/uploads/2025/07/Tivenix-and-CellCarta-e1752787079546.png","image_alt":"","stamp":"News","title":"Tivenix Partnership for Alzheimer’s Disease","description":"CellCarta has formed a strategic partnership with Tivenix to support the development and commercialization of their innovative diagnostic platform for Alzheimer’s disease and other neurodegenerative diseases. This platform aims to offer a sensitive,specific,and minimally invasive blood test for early disease diagnosis and patient stratification.
","stat_1_value":"","stat_1_label":"","stat_2_value":"","stat_2_label":"","stat_3_value":"","stat_3_label":"","button_text":"Learn More","button_url":"/news/cellcarta-and-tivenix-strategic-partnership/"}]}#-supreme-cellcarta-differentiators-8-735{items-data:[{"text":"Platform Agnostic Workflow"},{"text":"Custom Assay Development"},{"text":"Full Program Support"},{"text":"Complex Biomarker Expertise"},{"text":"Established Partnerships"}]}#-supreme-cellcarta-faq-11-735{items-data:[{"faq_question":"What CNS indications does CellCarta support?","faq_answer":"CellCarta’s neurosciences biomarker services support biomarker and assay development across a range of neurological disorders,including Alzheimer's disease,Parkinson's disease,Huntington's disease,Schizophrenia,and Multiple Sclerosis. Custom solutions are available for additional indications;contact the team to discuss your program's specific requirements.
"},{"faq_question":"What platforms are used for neuroscience programs?","faq_answer":"CellCarta leverages several technology platforms:Olink Proximity Extension Assay (PEA) technology for high-multiplex protein biomarker quantification (including Neurology and Neuro Exploratory panels),Meso Scale Discovery (MSD) for relative and absolute quantification in clinical matrices,MRM mass spectrometry for absolute quantification of biotherapeutics in brain tissue,CSF,and plasma,and NanoString nCounter for genomic analysis.
"},{"faq_question":"Does CellCarta support both discovery and regulated clinical phases?","faq_answer":"CellCarta’s neurosciences biomarker services supports biomarker discovery,protein quantification,and PK analysis across exploratory,translational,and regulated study phases,with integrated sample logistics and global facilities to support clinical trial needs.
"}]}#-supreme-cellcarta-indications-4-735{cards-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Alzheimers-Disease-139.jpg","image_alt":"Alzheimer’s Disease CSF biomarker assays","title":"Alzheimer’s Disease","description":"Validated MRM panels and APOE isotyping to measure NPTX2,VGF,SCG2,CgA,FABP3,and more."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Parkinsons-Disease-02.jpg","image_alt":"Parkinson’s Disease biomarker discovery","title":"Parkinson’s Disease","description":"Biomarker discovery and mass spectrometry (MS)-based panel development for Parkinson's programs."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Huntingtons-Disease-257.jpg","image_alt":"Huntington’s Disease custom biomarker panels","title":"Huntington’s Disease","description":"Custom biomarker panels and biotherapeutic characterization for Huntington’s research."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Schizophrenia-28.jpg","image_alt":"Schizophrenia protein biomarker quantification CNS","title":"Schizophrenia","description":"Protein biomarker quantification and assay development for CNS programs in schizophrenia."},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Cell-Phenotyping-94.jpg","image_alt":"Multiple Sclerosis T cell tracking and cytokine quantification","title":"Multiple Sclerosis","description":"Flow cytometry for T cell subset tracking,cytokine quantification,and biomarker assessment."}]}#-supreme-cellcarta-overview-3-735{stats-data:[{"number":"25+","label":"Years of expertise"},{"number":"8","label":"Global facilities"},{"number":"750+","label":"Employees"}]}#-supreme-cellcarta-tab-content-5-735{tabs-data:[{"tab_title":"Custom Neurology Panels","content_title":"","content_body":"We can implement off-the-shelf (OTS) panels for rapid CNS biomarker assessment,or develop and validate custom panels tailored to your study’s specifications,enabling disease monitoring,patient stratification,and therapeutic assessment.
\nBiomarker panels can be designed for exploratory,primary,and secondary endpoints,and may accommodate a range of relevant clinical sample types,including brain tissue,cerebrospinal fluid (CSF),and plasma.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Custom-Development-tab-556.jpg","image_alt":"Custom CNS biomarker panel development laboratory","tab_link_enabled":""},{"tab_title":"CNS Biomarkers","content_title":"","content_body":"We have developed and validated various analytical workflows for a range of relevant matrices,including CSF,brain tissue,and plasma,supporting both exploratory and regulated CNS programs.
\nThis includes a targeted MS-based panel that measures 142 Parkinson’s-related biomarkers.
\nWhether your study requires relative or absolute quantification of biologics and biomarkers,we can implement MS,nCounter,Olink®,and MSD®,for precise,accurate measurements.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-14-2-scaled.jpg","image_alt":"CSF biomarker analysis mass spectrometry laboratory"},{"tab_title":"CNS Sample Logistics","content_title":"","content_body":"CellCarta’s integrated sample logistics and global laboratory network support clinical trial specimen collection,processing,and analysis at scale,including for CNS studies requiring CSF sample handling.
\nWe can handle your study’s operational performance with ease,allowing your team to focus on the science at hand.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Sample-Logistics-tab-391.jpg","image_alt":"Clinical trial sample logistics management"}]}#-supreme-cellcarta-technology-6-735{cards-data:[{"card_title":"Olink™ PEA","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/Olink_PEA_Enhanced.png","image_alt":"Olink PEA technology high-multiplex protein biomarker quantification","card_description":"Olink PEA technology enables high-multiplex protein biomarker quantification from minimal sample volume. Neuroscience-specific panels include the Olink Neurology and Neuro Exploratory panel.
","card_link":"/capabilities/immunoassay-services/olink-pea-technology/","card_link_text":"Discover"},{"card_title":"Mass Spectrometry","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-20-2-scaled.jpg","image_alt":"MRM mass spectrometry PK assays for CNS programs","card_description":"MS-based assays support targeted and untargeted quantification of protein biomarkers and biotherapeutics in CSF,plasma,and brain tissue. CellCarta's MS workflows are applied across exploratory and regulated CNS studies.
","card_link":"/platforms/mass-spectrometry/","card_link_text":"Discover"},{"card_title":"MSD® Meso Scale Delivery","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-28-2-scaled.jpg","image_alt":"MSD Meso Scale Discovery multiplex immunoassay CNS","card_description":"MSD technology supports relative and absolute quantification of protein biomarkers in relevant biological matrices. MSD enables multiplex immunoassay applications relevant to CNS inflammation and neurodegeneration research.
","card_link":"/capabilities/immunoassay-services/meso-scale-discovery/","card_link_text":"Discover"}]}